JNJ-79032421 efficacy in xenograft models expressing low to high levels of MSLN. A, IHC was performed on xenograft tumors from CDX and PDX models [LXFA 289 (NSCLC), PAXF 1657 (pancreatic cancer), PRXF-MRI-H-1579 (prostate cancer), and LXFA 1041 (NSCLC)] with anti-MSLN antibody MNC3B30, which binds to the membrane-restricted region of MSLN and detects both cleaved C-terminus and full-length MSLN, but not sMSLN. Qualitative MSLN level (HI/MED/LO) assigned below the tumor model in parenthesis. Blue, cell nuclei (hematoxylin); brown, MSLN; magnification bar = 100 µm. B, Mean tumor volumes ±SEM over time in CDX models. Tumor cells were implanted on day 0. Mice were humanized with T cells (as indicated by down triangle) on the day of randomization, and treatment was initiated 1 day after T-cell implantation. For OVCAR-8 and OVCAR-8 K1/C8 studies, mice were treated intraperitoneally twice weekly for 3 weeks with JNJ-79032421 at 0.1 and 0.01 mg/kg and MNC3B232 at 0.1 mg/kg. For SK-OV-3, mice were treated intraperitoneally twice weekly for 4 weeks with 0.1, 0.5, and 2.5 mg/kg JNJ-79032421 and 0.1 mg/kg MNC3B232. The dosing period is indicated by the bar below the X-axis. *Denotes significant difference (P ≤ 0.05) of the JNJ-79032421 or MNC3B232 treatment group compared with the control (DPBS) group. C, Mean tumor volumes ±SEM over time upon treatment of JNJ-79032421 in PDX mouse models. Tumor cells were implanted on day 0. Mice were humanized with T cells (as indicated by down green triangle) on the day of randomization, and treatment was initiated 1 day after T-cell implantation. Mice were treated intraperitoneally twice weekly for 3 weeks on days 19, 22, 26, 29, 33, and 36 (LXFA 289 MSLNHI+ and PRXF-MRI-H 1579 MSLNMED+) and on days 18, 21, 25, 28, 32, and 35 (PAXF 1657 MSLNMED+/HI+ and LXFA 1041 MSLNMED+/LO+). The dosing period is indicated by the bar below the X-axis. *Denotes significant difference (P ≤ 0.05) of JNJ-79032421 treatment groups compared with the DPBS group (LXFA 289, PRXF-MRI-H 1579, and LXFA 1041) or between groups treated with nullxCD3 and JNJ-79032421 (PAXF 1657). JNJ-79032421 at 0.1 mg/kg resulted in >100% ΔTGI of LXFA 289, PRXF-MRI-H 1579, and LXFA 1041 tumors and 69% ΔTGI of PAXF 1657 tumors with greater activity seen at higher doses. Levels of MSLN expression assigned based on IHC in A.